{
  "abstract": "Background:: Type 2 (T2) biologics represent a promising treatment option for chronic obstructive pulmonary disease (COPD) patients with eosinophilic inflammation.\n\nObjectives:: To evaluate the prevalence of stable COPD patients who may be eligible for T2 biologics.\n\nDesign:: Real-world, retrospective, monocentric study in COPD patients undergoing inpatient pulmonary rehabilitation.\n\nMethods:: Clinical, functional, and inflammatory data were collected. Patients were considered eligible for T2 biologic therapy whether they were receiving optimized inhaled therapy and had a history of ⩾2 moderate and/or ⩾1 severe exacerbations in the previous year, together with a blood eosinophil count ⩾300 cells/μL.\n\nResults:: Among 441 patients, 21.5% had blood eosinophil counts ⩾300 cells/μL and 6.8% fulfilled the combined eligibility criteria. A high burden of respiratory and cardiometabolic comorbidities and increased cardiovascular risk was observed in the overall population.\n\nConclusion:: Only a subgroup of patients seems eligible for biologics, treatment escalation should be based on optimized standard care management and patient phenotyping",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": "brief report",
  "arxiv": null,
  "author_total": 7,
  "authors": [
    {
      "name": "Marco Vanetti",
      "orcid": "0009-0007-3782-5021"
    },
    {
      "name": "Dina Visca",
      "orcid": "0000-0003-2298-1623"
    },
    {
      "name": "Francesco Ardesi",
      "orcid": "0000-0003-3420-4012"
    },
    {
      "name": "Antonia M. Taglioretti"
    },
    {
      "name": "Martina Zappa"
    },
    {
      "name": "Patrizia Pignatti"
    },
    {
      "name": "Antonio Spanevello"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/0gqqy7rsd0zq5.bib",
  "cited_by": 0,
  "doi": "10.1177/17534666261471839",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13724964/",
  "id": "0gqqy7rsd0zq5",
  "issns": [
    "1753-4658",
    "1753-4666"
  ],
  "landing_url": "https://doi.org/10.1177/17534666261471839",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Brief Report"
    ],
    [
      "openalex",
      "2740|Chronic Obstructive Pulmonary Disease (COPD) Research"
    ]
  ],
  "openalex": "W7213666141",
  "pdf_url": null,
  "pmcid": "PMC13724964",
  "pmid": "42760892",
  "published": "2026-09-19",
  "publisher": "SAGE Publications",
  "ris": "https://research.draconitic.com/paper/0gqqy7rsd0zq5.ris",
  "sources": [
    {
      "first_seen": "2026-11-04T12:23:26Z",
      "native_id": "PMC13724964",
      "source": "pmc",
      "url": "https://doi.org/10.1177/17534666261471839"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2740|Chronic Obstructive Pulmonary Disease (COPD) Research",
      "subfield": "general"
    }
  ],
  "title": "Blood eosinophils in COPD: are biologics for everyone?",
  "title_text": "Blood eosinophils in COPD: are biologics for everyone?",
  "type": "peer-reviewed",
  "updated_at": "2026-11-06T12:21:20Z",
  "url": "https://research.draconitic.com/paper/0gqqy7rsd0zq5",
  "venue": "Therapeutic Advances in Respiratory Disease",
  "versions": []
}